1
|
Camassa N, Liguori M, Pansini M, Troccoli R, Carretta D, Dachille A, Giardinelli F, Signore N, D‘agostino C. P269 LOCAL ULTRASOUND–FACILITATED THROMBOLYSIS IN ACUTE PULMONARY EMBOLISM: HAS A SPACE? Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac012.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Acute pulmonary embolism (PE) has an annual incidence of 48 patients per 100,000 with a mortality rate of 10%, few hours after the onset of symptoms. The use of full dose of thrombolytic agent is currently the treatment of choice in acute PE at intermediate and high risk, although its contraindications are well known. An alternative choice is delivered, via percutaneous femoral or jugular venous access, infusion catheters in the pulmonary artery (PA), in order to perform a local thrombolysis (based on a map of thrombus distribution observed at pulmonary CT), with a lower dose of trobolytic agent (rTPA) in a limited time, with a core for emission of ultrasound waves capable of breaking the mesh of the thrombus. Data from the KNOCOUT PE registry show a reduced frequency of fatal intracranial hemorrhage (ICH 2.5%), compared with the full dose of rTPA. Since February 2021 we have treated 7 patients with PE, all with cTnI, D–dimer and high NT–ProBNP and with pulmonary CT finding of large thrombus burden with pruning of peripheral pulmonary branches compatible with the diagnosis of PE at high and intermediate risk in patients with complex comorbidities (significant PESI and simplified PESI). On admission to the ICU all patients were with BP < 100 mmHg, RR > 20/min, satO2 < 90% and HR > 100 bpm. In echocardiogram all were with impaired RV (RV/LF ratio >1 and TAPSE <15mm). All patients was treated with UHF, 1 in fondaparinux for thrombocytopenia. At time between 4h and 8gg from the onset of symptoms, all patients underwent placement of 1 or 2 catheters in right and/or left PA, 106 cm and 135 cm length with zone of interest between 18/32 cm. When possible, hemodynamic parameters were evaluated: PAPm, cardiac output, and stroke volume to characterize the associated hemodynamic deterioration. 12mg of rtPA per catheter was administered over 12 hours. In 3 patients an echocardiogram was performed at 6 hours. In all at 24 hours, vital and laboratory parameters were measured, and in one patient, right heart catheterization was repeated. In no patient was treatment discontinued early, nor were ICH or minor bleeding recorded. Low dose of rtPA allowed use of the technique in patients with severe comorbidities at the limit of thrombolysis use, in the presence of marked RV distress and severe hemodynamic instability. Trials are in progress to shorten the time and therefore reduce the dose of rTPA with equal effectiveness on the clinical course of acute PE.
Collapse
|
2
|
Mascia E, Clarelli F, Zauli A, Guaschino C, Sorosina M, Barizzone N, Basagni C, Santoro S, Ferrè L, Bonfiglio S, Biancolini D, Pozzato M, Guerini FR, Protti A, Liguori M, Moiola L, Vecchio D, Bresolin N, Comi G, Filippi M, Esposito F, D'Alfonso S, Martinelli-Boneschi F. Burden of rare coding variants in an Italian cohort of familial multiple sclerosis. J Neuroimmunol 2022; 362:577760. [PMID: 34922125 DOI: 10.1016/j.jneuroim.2021.577760] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 10/18/2021] [Accepted: 10/31/2021] [Indexed: 12/30/2022]
Abstract
BACKGROUND Multiple Sclerosis (MS) is a chronic inflammatory and neurodegenerative demyelinating disease of the central nervous system. It is a complex and heterogeneous disease caused by a combination of genetic and environmental factors, and it can cluster in families. OBJECTIVE to evaluate at gene-level the aggregate contribution of predicted damaging low-frequency and rare variants to MS risk in multiplex families. METHODS We performed whole exome sequencing (WES) in 28 multiplex MS families with at least 3 MS cases (81 affected and 42 unaffected relatives) and 38 unrelated healthy controls. A gene-based burden test was then performed, focusing on two sets of candidate genes: i) literature-driven selection and ii) data-driven selection. RESULTS We identified 11 genes enriched with predicted damaging low-frequency and rare variants in MS compared to healthy individuals. Among them, UBR2 and DST were the two genes with the strongest enrichment (p = 5 × 10-4 and 3 × 10-4, respectively); interestingly enough the association signal in UBR2 is driven by rs62414610, which was present in 25% of analysed families. CONCLUSION Despite limitations, this is one of the first studies evaluating the aggregate contribution of predicted damaging low-frequency and rare variants in MS families using WES data. A replication effort in independent cohorts is warranted to validate our findings and to evaluate the role of identified genes in MS pathogenesis.
Collapse
|
3
|
Ricciardone A, Dall'Armi LV, Bartolo N, Bertacca D, Liguori M, Matarrese S. Cross-Correlating Astrophysical and Cosmological Gravitational Wave Backgrounds with the Cosmic Microwave Background. PHYSICAL REVIEW LETTERS 2021; 127:271301. [PMID: 35061444 DOI: 10.1103/physrevlett.127.271301] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Accepted: 11/11/2021] [Indexed: 06/14/2023]
Abstract
General relativity provides us with an extremely powerful tool to extract at the same time astrophysical and cosmological information from the stochastic gravitational-wave backgrounds (SGWBs): the cross-correlation with other cosmological tracers, since their anisotropies share a common origin and the same perturbed geodesics. In this Letter we explore the cross-correlation of the cosmological and astrophysical SGWBs with cosmic microwave background (CMB) anisotropies, showing that future GW detectors, such as LISA or BBO, have the ability to measure such cross-correlation signals. We also present, as a new tool in this context, constrained realization maps of the SGWBs extracted from the high-resolution CMB Planck maps. This technique allows, in the low-noise regime, to faithfully reconstruct the expected SGWB map by starting from CMB measurements.
Collapse
|
4
|
Scharf C, Di Brizzi EV, Pellerone S, Liguori M, Giorgio CMR, Argenziano G. Nevocentric erythema multiforme after SARS-COV-2 vaccine. J Eur Acad Dermatol Venereol 2021; 36:e30-e32. [PMID: 34547145 PMCID: PMC8657514 DOI: 10.1111/jdv.17688] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 09/01/2021] [Accepted: 09/16/2021] [Indexed: 11/27/2022]
|
5
|
Elia AM, Rojas P, Liguori M, Gonzalez P, Caillet I, Martínez Vazquez P, Burruchaga J, Gass H, Lanari C. Abstract P5-05-14: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-05-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Elia AM, Rojas P, Liguori M, Gonzalez P, Caillet I, Martínez Vazquez P, Burruchaga J, Gass H, Lanari C. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-05-14.
Collapse
|
6
|
Liguori M, Lanari C, Gass H, Rojas P, Elia A, Martinez Vazquez P, Burruchaga J, Gonzalez P, Caillet Bois I, Ventura C, San Martin G, Castets A, Lovisi S, Acosta Haab G, Lamb C, Fabris V, Novaro V, Molinolo A. Abstract OT1-04-02: Mifepristone treatment for breast cancer patients expressing levels of progesterone receptor isoform A (PRA) higher than those of isoform B (PRB). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot1-04-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Seventy percent of breast cancers express estrogen (ER) and progesterone receptors (PR) and respond to antiestrogen therapies. Emerging evidence from experimental studies and human epidemiology, points to a relevant role for progestins in breast carcinogenesis and cancer growth. Others and we have proposed that there is a role for antiprogestins in the therapeutic armamentarium, but the challenge remains to identify which patients would benefit from targeting the PR in addition to ER. Preclinical data indicates that antiprogestins block cell proliferation and increase apoptosis only in ER+ breast cancers expressing levels of PRA higher than those of PRB. The aim of this study is to evaluate the therapeutic effects of Mifepristone (MFP) on breast cancer patients selected by their PRA/PRB isoform ratio, for 14 days in between core biopsy and surgery (MIPRA trial ClinicalTrials.gov Identifier: NCT02651844). Methods: This is an open label, interventional with single group assignment study. We perform core biopsies on menopausal patients with clinically palpable breast cancers larger than 1.5 cm to confirm diagnosis. We will assess the PRA/PRB ratio by western blotting in frozen samples and total PR in formalin-fixed samples by immunohistochemistry (IHC). Twenty eligible PR+ patients (PR > 50 %) with PRA/PRB ≥1.5 who have signed consent forms, and meet the inclusion criteria will be recruited. Patients will be treated for 14 days with MFP p.o 200 mg. Surgery will be performed on day 15. Samples will be frozen for molecular studies or fixed for IHC. The primary outcome is the evaluation of Ki-67 staining pre- and post treatment. Secondary outcomes include comparatively expression of proliferation/apoptosis/PR signaling markers in core and surgical biopsy samples. Other pre-specified outcomes include molecular profiling, study of liquid biopsies, mammography, and ultrasound studies. Wilcoxon signed rank test will be used to evaluate differences in biomarker expression between core biopsy and surgical samples of each patient.
Citation Format: Liguori M, Lanari C, Gass H, Rojas P, Elia A, Martinez Vazquez P, Burruchaga J, Gonzalez P, Caillet Bois I, Ventura C, San Martin G, Castets A, Lovisi S, Acosta Haab G, Lamb C, Fabris V, Novaro V, Molinolo A. Mifepristone treatment for breast cancer patients expressing levels of progesterone receptor isoform A (PRA) higher than those of isoform B (PRB) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT1-04-02.
Collapse
|
7
|
Liguori M, Tagarelli G, Romeo N, Bagalà A, Spadafora P. Identification of a patient affected by "Juvenile-chronic" Tay Sachs disease in South Italy. Neurol Sci 2016; 37:1883-1885. [PMID: 27351546 DOI: 10.1007/s10072-016-2646-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Accepted: 06/22/2016] [Indexed: 10/21/2022]
|
8
|
Ciurlionis R, Liguori M, Blomme E. Comparison of Real‐Time Impedance Profiles of HepaRG Cells and Primary Human Hepatocytes to Identify Biliary Toxicants. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.937.10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
9
|
Ade PAR, Aghanim N, Ahmed Z, Aikin RW, Alexander KD, Arnaud M, Aumont J, Baccigalupi C, Banday AJ, Barkats D, Barreiro RB, Bartlett JG, Bartolo N, Battaner E, Benabed K, Benoît A, Benoit-Lévy A, Benton SJ, Bernard JP, Bersanelli M, Bielewicz P, Bischoff CA, Bock JJ, Bonaldi A, Bonavera L, Bond JR, Borrill J, Bouchet FR, Boulanger F, Brevik JA, Bucher M, Buder I, Bullock E, Burigana C, Butler RC, Buza V, Calabrese E, Cardoso JF, Catalano A, Challinor A, Chary RR, Chiang HC, Christensen PR, Colombo LPL, Combet C, Connors J, Couchot F, Coulais A, Crill BP, Curto A, Cuttaia F, Danese L, Davies RD, Davis RJ, de Bernardis P, de Rosa A, de Zotti G, Delabrouille J, Delouis JM, Désert FX, Dickinson C, Diego JM, Dole H, Donzelli S, Doré O, Douspis M, Dowell CD, Duband L, Ducout A, Dunkley J, Dupac X, Dvorkin C, Efstathiou G, Elsner F, Enßlin TA, Eriksen HK, Falgarone E, Filippini JP, Finelli F, Fliescher S, Forni O, Frailis M, Fraisse AA, Franceschi E, Frejsel A, Galeotta S, Galli S, Ganga K, Ghosh T, Giard M, Gjerløw E, Golwala SR, González-Nuevo J, Górski KM, Gratton S, Gregorio A, Gruppuso A, Gudmundsson JE, Halpern M, Hansen FK, Hanson D, Harrison DL, Hasselfield M, Helou G, Henrot-Versillé S, Herranz D, Hildebrandt SR, Hilton GC, Hivon E, Hobson M, Holmes WA, Hovest W, Hristov VV, Huffenberger KM, Hui H, Hurier G, Irwin KD, Jaffe AH, Jaffe TR, Jewell J, Jones WC, Juvela M, Karakci A, Karkare KS, Kaufman JP, Keating BG, Kefeli S, Keihänen E, Kernasovskiy SA, Keskitalo R, Kisner TS, Kneissl R, Knoche J, Knox L, Kovac JM, Krachmalnicoff N, Kunz M, Kuo CL, Kurki-Suonio H, Lagache G, Lähteenmäki A, Lamarre JM, Lasenby A, Lattanzi M, Lawrence CR, Leitch EM, Leonardi R, Levrier F, Lewis A, Liguori M, Lilje PB, Linden-Vørnle M, López-Caniego M, Lubin PM, Lueker M, Macías-Pérez JF, Maffei B, Maino D, Mandolesi N, Mangilli A, Maris M, Martin PG, Martínez-González E, Masi S, Mason P, Matarrese S, Megerian KG, Meinhold PR, Melchiorri A, Mendes L, Mennella A, Migliaccio M, Mitra S, Miville-Deschênes MA, Moneti A, Montier L, Morgante G, Mortlock D, Moss A, Munshi D, Murphy JA, Naselsky P, Nati F, Natoli P, Netterfield CB, Nguyen HT, Nørgaard-Nielsen HU, Noviello F, Novikov D, Novikov I, O'Brient R, Ogburn RW, Orlando A, Pagano L, Pajot F, Paladini R, Paoletti D, Partridge B, Pasian F, Patanchon G, Pearson TJ, Perdereau O, Perotto L, Pettorino V, Piacentini F, Piat M, Pietrobon D, Plaszczynski S, Pointecouteau E, Polenta G, Ponthieu N, Pratt GW, Prunet S, Pryke C, Puget JL, Rachen JP, Reach WT, Rebolo R, Reinecke M, Remazeilles M, Renault C, Renzi A, Richter S, Ristorcelli I, Rocha G, Rossetti M, Roudier G, Rowan-Robinson M, Rubiño-Martín JA, Rusholme B, Sandri M, Santos D, Savelainen M, Savini G, Schwarz R, Scott D, Seiffert MD, Sheehy CD, Spencer LD, Staniszewski ZK, Stolyarov V, Sudiwala R, Sunyaev R, Sutton D, Suur-Uski AS, Sygnet JF, Tauber JA, Teply GP, Terenzi L, Thompson KL, Toffolatti L, Tolan JE, Tomasi M, Tristram M, Tucci M, Turner AD, Valenziano L, Valiviita J, Van Tent B, Vibert L, Vielva P, Vieregg AG, Villa F, Wade LA, Wandelt BD, Watson R, Weber AC, Wehus IK, White M, White SDM, Willmert J, Wong CL, Yoon KW, Yvon D, Zacchei A, Zonca A. Joint analysis of BICEP2/keck array and Planck Data. PHYSICAL REVIEW LETTERS 2015; 114:101301. [PMID: 25815919 DOI: 10.1103/physrevlett.114.101301] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Indexed: 06/04/2023]
Abstract
We report the results of a joint analysis of data from BICEP2/Keck Array and Planck. BICEP2 and Keck Array have observed the same approximately 400 deg^{2} patch of sky centered on RA 0 h, Dec. -57.5°. The combined maps reach a depth of 57 nK deg in Stokes Q and U in a band centered at 150 GHz. Planck has observed the full sky in polarization at seven frequencies from 30 to 353 GHz, but much less deeply in any given region (1.2 μK deg in Q and U at 143 GHz). We detect 150×353 cross-correlation in B modes at high significance. We fit the single- and cross-frequency power spectra at frequencies ≥150 GHz to a lensed-ΛCDM model that includes dust and a possible contribution from inflationary gravitational waves (as parametrized by the tensor-to-scalar ratio r), using a prior on the frequency spectral behavior of polarized dust emission from previous Planck analysis of other regions of the sky. We find strong evidence for dust and no statistically significant evidence for tensor modes. We probe various model variations and extensions, including adding a synchrotron component in combination with lower frequency data, and find that these make little difference to the r constraint. Finally, we present an alternative analysis which is similar to a map-based cleaning of the dust contribution, and show that this gives similar constraints. The final result is expressed as a likelihood curve for r, and yields an upper limit r_{0.05}<0.12 at 95% confidence. Marginalizing over dust and r, lensing B modes are detected at 7.0σ significance.
Collapse
|
10
|
Mike A, Glanz B, Hildenbrand P, Meier D, Bolden K, Dell'Oglio E, Healy B, Liguori M, Bakshi R, Guttmann C. Impact of cortical lesions identified by routine 3T MRI imaging on cognitive performance of patients with multiple sclerosis. J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.1448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
Magariello A, Tortorella C, Patitucci A, Tortelli R, Liguori M, Mazzei R, Conforti FL, Citrigno L, Ungaro C, Simone IL, Muglia M. First mutation in the nuclear localization signal sequence of spastin protein identified in a patient with hereditary spastic paraplegia. Eur J Neurol 2012; 20:e22-3. [DOI: 10.1111/ene.12000] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2012] [Accepted: 08/27/2012] [Indexed: 11/28/2022]
|
12
|
Zoccolella S, Vecchio E, Direnzo V, Luciannatelli E, Brancasi B, Bellomo R, Liguori M, Tortorella C. Concomitant myotonic dystrophy type 1, CIDP-like neuropathy and Hashimoto thyroiditis: a causal link? Eur J Neurol 2012; 19:e117-8. [DOI: 10.1111/j.1468-1331.2012.03820.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Mike A, Glanz BI, Hildenbrand P, Meier D, Bolden K, Liguori M, Dell'Oglio E, Healy BC, Bakshi R, Guttmann CRG. Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging. AJNR Am J Neuroradiol 2011; 32:515-21. [PMID: 21310857 DOI: 10.3174/ajnr.a2340] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
BACKGROUND AND PURPOSE Histopathologic studies have reported widespread cortical lesions in MS; however, in vivo detection by using routinely available pulse sequences is challenging. We investigated the relative frequency and subtypes of cortical lesions and their relationships to white matter lesions and cognitive and physical disability. MATERIALS AND METHODS Cortical lesions were identified and classified on the basis of concurrent review of 3D FLAIR and 3D T1-weighted IR-SPGR 3T MR images in 26 patients with MS. Twenty-five patients completed the MACFIMS battery. White matter lesion volume, cortical lesion number, and cortical lesion volume were assessed. RESULTS Overall, 249 cortical lesions were detected. Cortical lesions were present in 24/26 patients (92.3%) (range per patient, 0-30; mean, 9.6 ± 8.8). Most (94.4%, n = 235) cortical lesions were classified as mixed cortical-subcortical (type I); the remaining 5.6% (n = 14) were classified as purely intracortical (type II). Subpial cortical lesions (type III) were not detected. White matter lesion volume correlated with cortical lesion number and cortical lesion volume (r(S) = 0.652, r(S) = 0.705, respectively; both P < .001). After controlling for age, depression, and premorbid intelligence, we found that all MR imaging variables (cortical lesion number, cortical lesion volume, white matter lesion volume) correlated with the SDMT score (R(2) = 0.513, R(2) = 0.449, R(2) = 0.418, respectively; P < .014); cortical lesion number also correlated with the CVLT-II scores (R(2) = 0.542-0.461, P < .043). The EDSS scores correlated with cortical lesion number and cortical lesion volume (r(S) = 0.472, r(S) = 0.404, respectively; P < .05), but not with white matter lesion volume. CONCLUSIONS Our routinely available imaging method detected many cortical lesions in patients with MS and was useful in their precise topographic characterization in the context of the gray matter-white matter junction. Routinely detectable cortical lesions were related to physical disability and cognitive impairment.
Collapse
|
14
|
Riccioni C, Sarcinella R, Izzo A, Palermo G, Liguori M, Caliumi C, Carloni E, Paolucci AM, D'andrea P, Pompili S. Rehabilitative treatment in peripheral artery disease: protocol application and follow-up. Minerva Cardioangiol 2010; 58:551-565. [PMID: 20948502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
AIM Peripheral arterial disease (PAD) is a chronic figure suitable to be treated at the II stage to prevent the extreme developments both of the critical limb ischemia and the amputation, as well. The aim of this study was to establish a rehabilitation program (pharmacological and physical) focused not only on the improvement of the flow but also on the metabolic rebalancing in the claudicant limb. METHODS The study enrolled 222 patients, (125 non-diabetics and 97 diabetics): 54 II A and 168 II B stage; 172 patients (131 II B and 41 II A; 104 non-diabetics and 68 diabetics) were submitted to iv. L-propionil carnytine (Lpc) and physical training on treadmill or exercise bike and 50 patients to iv. therapy alone. Instrumental (Rheoscreen, Oximetry, ABI, walking distance measurement) and clinical checks (questionnaire - Appendix 1) were performed at days: T0, T45,T 90,T180, T230 and during the follow up stated at T 90,T180,T360 from T 230 (end of DH). RESULTS A significant increasing of the walking distance has been reached in the group undergoing the rehabilitation program. Treadmill: non-diabetics +261.48% at 0% and +122.53% at slope 10% (T230) further increasing to +502.31% at 0% and +289.42% at slope 10% (T360); diabetics: + 158.49% at T0 and + 98.26% at slope 10% (T230) further increased to +287.74% at 0% and +197.39% at 10% (T360) in comparison with the group which had only iv. Lpc : non-diabetics +141.63% at 0% and +104.08% at slope 10% (T230) further increased to +202.064% at 0% and +155.10% at slope 10% (T360); diabetics: +109.124% at T0 and +100% at slop 10% (T230) further increased to +171.08% at 0% and +140% at 10% (T360) . Exercise bike: non-diabetics: +170.27% at T230 in comparison T0 increased to +305.4% at T360; diabetics: +166.66 at T230 reaching +288.88% at T 360. CONCLUSION Our rehabilitative program gives not only good results at the end of the treatment but mainly stable, with the chance to reach further improving of both walking distance and quality of life, particularly in those patients which observe constantly the physical training.
Collapse
|
15
|
Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, Khoury S, Hartzmann R, Fernandez-Vina M, Hafler DA, Weiner HL, Guttmann CRG, De Jager PL. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology 2010; 75:634-40. [PMID: 20713950 DOI: 10.1212/wnl.0b013e3181ed9c9c] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE In addition to the main multiple sclerosis (MS) major histocompatibility complex (MHC) risk allele (HLA DRB1*1501), investigations of the MHC have implicated several class I MHC loci (HLA A, HLA B, and HLA C) as potential independent MS susceptibility loci. Here, we evaluate the role of 3 putative protective alleles in MS: HLA A*02, HLA B*44, and HLA C*05. METHODS Subjects include a clinic-based patient sample with a diagnosis of either MS or a clinically isolated syndrome (n = 532), compared to subjects in a bone marrow donor registry (n = 776). All subjects have 2-digit HLA data. Logistic regression was used to determine the independence of each allele's effect. We used linear regression and an additive model to test for correlation between an allele and MRI and clinical measures of disease course. RESULTS After accounting for the effect of HLA DRB1*1501, both HLA A*02 and HLA B*44 are validated as susceptibility alleles (p(A*02) 0.00039 and p(B*44) 0.00092) and remain significantly associated with MS susceptibility in the presence of the other allele. Although A*02 is not associated with MS outcome measures, HLA B*44 demonstrates association with a better radiologic outcome both in terms of brain parenchymal fraction and T2 hyperintense lesion volume (p = 0.03 for each outcome). CONCLUSION The MHC class I alleles HLA A*02 and HLA B*44 independently reduce susceptibility to MS, but only HLA B*44 appears to influence disease course, preserving brain volume and reducing the burden of T2 hyperintense lesions in subjects with MS.
Collapse
|
16
|
Moscufo N, Meier D, Liguori M, Schmidt J, Panzer V, Wolfson L, Guttmann C. 024 PROGRESSION OF MOBILITY IMPAIRMENT AND BRAIN WHITE MATTER LESION VOLUME IN THE ELDERLY: A TWO-YEAR LONGITUDINAL STUDY. Parkinsonism Relat Disord 2010. [DOI: 10.1016/s1353-8020(10)70025-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
Ungaro C, Mazzei R, Conforti FL, Sprovieri T, Servillo P, Liguori M, Citrigno L, Gabriele AL, Magariello A, Patitucci A, Muglia M, Quattrone A. CADASIL: extended polymorphisms and mutational analysis of the NOTCH3 gene. J Neurosci Res 2009; 87:1162-7. [PMID: 19006080 DOI: 10.1002/jnr.21935] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
CADASIL is a cerebrovascular disease caused by mutations in the NOTCH3 gene. Most mutations result in a gain or loss of cysteine residue in one of the 34 epidermal growth factor-like repeats in the extracellular domain of the Notch3 protein, thus sparing the number of cysteine residues. To date, more than 130 different mutations in the NOTCH3 gene have been reported in CADASIL patients, of which 95% are missense point mutations. Many polymorphisms have also been identified in the NOTCH3 coding sequence, some of them leading to amino acid substitutions. The aim of the present study was to analyze the NOTCH3 gene in a large group of patients affected by leukoencephalopathy and to investigate the presence of genetic variants. The molecular analysis revealed several nucleotide alterations. In particular, we identified 20 different mutations, 22 polymorphisms, and 8 genetic variants of unknown pathological significance never reported previously. We hope that this NOTCH3 gene mutational analysis, performed in such a significant number of unrelated and related patients affected by leukoencephalopathy, will help in molecular screening for the NOTCH3 gene, thus contributing to enlargement of the NOTCH3 gene variation database.
Collapse
|
18
|
Martino D, Muglia M, Abbruzzese G, Berardelli A, Girlanda P, Liguori M, Livrea P, Quattrone A, Roselli F, Sprovieri T, Valente EM, Defazio G. Brain-derived neurotrophic factor and risk for primary adult-onset cranial-cervical dystonia. Eur J Neurol 2009; 16:949-52. [PMID: 19473353 DOI: 10.1111/j.1468-1331.2009.02633.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND AND PURPOSE Adult-onset dystonia may be related, amongst other factors, to abnormal neuronal plasticity in cortical and subcortical structures. Brain-derived neurotrophic factor is a major modulator of synaptic efficiency and neuronal plasticity. Recent works documented that a single nucleotide polymorphism (SNP) of the BDNF gene, the Val66Met SNP, modulates short-term plastic changes within motor cortical circuits. In this study we aimed at exploring the effect of this SNP upon the risk of developing common forms of primary adult-onset dystonia. METHODS We explored the influence of the Val66Met SNP of the BDNF gene on the risk of cranial and cervical dystonia in a cohort of 156 Italian patients and 170 age- and gender-matched healthy control subjects drawn from the same population. RESULTS The presence of the rare Met allele was not significantly associated with the diagnosis of dystonia (age- and gender-adjusted odds ratios of 1.22, P = 0.38). The study had a >90% power to detect a 50% change in the risk of developing cranial-cervical dystonia associated with the presence of the Met allele. Moreover, there was no relationship between Val66Met SNP and age at dystonia onset or type of dystonia. CONCLUSION Our data do not support the common variant Val66Met of the BDNF gene as an etiologic factor shared by the various forms of primary adult-onset dystonia.
Collapse
|
19
|
Valentino P, Labate A, Nisticò R, Pirritano D, Cerasa A, Liguori M, Bastone L, Crescibene L, Quattrone A. Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis. Mult Scler 2009; 15:114-5. [DOI: 10.1177/1352458508096685] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Objectives The aim of this study was to correlate the brain atrophy with serum levels of anti-GM1 antibodies in patients with relapsing–remitting multiple sclerosis (RRMS). Methods Plasma sample from 52 patients with RRMS and 65 healthy controls were examined for anti-GM1 antibodies. Patients with RRMS underwent to MRI study with automated method called SIENAX that calculated an estimate of gray matter (GMV) and white matter (WMV) volumes. Results The percentage of RRMS patients with increased anti-GM1 was 37.8%. Elevated levels of anti-GM1 antibodies did not correlate with brain atrophy. Conclusions Anti-GM1 antibodies do not represent a marker of axonal damage in patients with RRMS.
Collapse
|
20
|
Liguori M, Mazzei R, Ungaro C, Simone IL, Gambardella A, Plasmati I, Fera F, Aguglia U, Lanza P, Bono F, Chiumarulo L, Conforti FL, Consoli D, Quattrone A. CONVENTIONAL MRI AND NOTCH3 GENE SCREENING IN SPORADIC CADASIL. Neurology 2008; 72:469-71. [DOI: 10.1212/01.wnl.0000336342.04778.2b] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
21
|
Riccioni C, Sarcinella R, Palermo G, Izzo A, Liguori M, Koverech A, Messano M, Virmani A. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. INT ANGIOL 2008; 27:253-259. [PMID: 18506129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
AIM The effectiveness of propionyl-L-carnitine (PLC) monotherapy regimen alone or in association with pulsed muscular compression was compared to the physical therapy by itself against obliterant arteriopathy Leriche Fontaine stage II. PLC is involved in cellular metabolism and is transformed into two active substances, free L-carnitine and propionyl-coenzyme A in the mitochondria, which take part in fatty acid transfer and in the citric acid cycle, respectively. METHODS Forty-two patients with arterial disease were selected (22 males and 20 females; mean age: 62+/-8 years; 21 type 2 diabetic [DB] and 21 non-DB [NDB]). At enrollment all patients completed a symptoms questionnaire enabling both clinical and social evaluation of the impact of the arteriopathy on the quality of life. Then, patients had: routine blood samples, echo duplex scan; evaluation of the ankle/arm (Winsor) index; impedance plethysmography (Rheoscreen) to measure the crest time (CT), index of the pathological changes due to the sclerosis on the vascular wall, and measurement of walking distance by means of treadmill test. Patients were randomized in three groups, each of them composed by 14 patients (7 DB and 7 NDB): the first group was submitted to infusional PLC therapy at a dosage of 4 fl (total: 1,200 mg PLC) in 250 cc of physiological solution for 5 days a week for 4 weeks; the second group was treated with PLC in association with pulsed muscular compression therapy by Vascupump (5 sessions a week for 4 weeks); the third group was submitted only to Vascupump. RESULTS The efficacy of both PLC and Vascupump in the treatment of the peripheral vasculopathies was confirmed. From a subjective point of view, patients referred benefits both in clinical terms, i.e. increased walking distance (average increaseaegroup I: DB 102%, NDB 118%; group II: DB 94%, NDB 193%; group III: DB 33%, NDB 67%) and of decreased intensity of the calf pain from the quality of life questionnaire (21.5 to 10.7). The instrumental parameters showed a trend towards normality, i.e decrease in CT and an increase of the Winsor index, indicators of increased peripheral blood circulation. CONCLUSION Combined pharmaco- and physical therapy was most efficient treatment regime and best results were seen in NDB compared to the DB patients.
Collapse
|
22
|
Liguori M, Russa A, Manna I, Andreoli V, Caracciolo M, Spadafora P, Cittadella R, Quattrone A. A phenotypic variation of dominant optic atrophy and deafness (ADOAD) due to a novel OPA1 mutation. J Neurol 2008; 255:127-9. [DOI: 10.1007/s00415-008-0571-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2006] [Revised: 01/11/2007] [Accepted: 01/24/2007] [Indexed: 10/22/2022]
|
23
|
Spadafora P, Annesi G, Liguori M, Tarantino P, Cutuli N, Carrideo S, Cirò Candiano IC, De Marco EV, Civitelli D, Annesi F, Giuffrida S, Quattrone A. Gene dosage influences the age at onset of SCA2 in a family from southern Italy. Clin Genet 2007; 72:381-3. [PMID: 17850638 DOI: 10.1111/j.1399-0004.2007.00868.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Andreoli V, Cittadella R, Valentino P, Condino F, La Russa A, Liguori M, Manna I, Spadafora P, Nisticò R, Pirritano D, Clodomiro A, Quattrone A. The role of VLA4 polymorphisms in multiple sclerosis: An association study. J Neuroimmunol 2007; 189:125-8. [PMID: 17609118 DOI: 10.1016/j.jneuroim.2007.06.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2007] [Revised: 05/29/2007] [Accepted: 06/20/2007] [Indexed: 11/24/2022]
Abstract
Lymphocyte and monocyte brain infiltration determines inflammation in multiple sclerosis. The trafficking of these cells into the CNS results from the VLA-4 binding with its ligand on brain endothelial cells. MS patients treated with an antibody against the alpha-4 subunit, which inhibits this interaction, prevents brain lesion development. We investigated the association between VLA-4 gene polymorphisms and MS in a study on 275 patients and 255 controls. No differences were detected, thus suggesting that these polymorphisms are not a significant genetic risk factor for susceptibility to MS in Italy.
Collapse
|
25
|
Liguori M, Fera F, Gioia MC, Valentino P, Manna I, Condino F, Cerasa A, La Russa A, Clodomiro A, Paolillo A, Nisticò R, Vercillo L, Cittadella R, Quattrone A. Investigating the role of brain-derived neurotrophic factor in relapsing-remitting multiple sclerosis. GENES BRAIN AND BEHAVIOR 2007; 6:177-83. [PMID: 16740142 DOI: 10.1111/j.1601-183x.2006.00245.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Multiple sclerosis (MS) is a common, heterogeneous disorder of the central nervous system with a complex trait composed of both genetic and environmental factors. Recently, scientific interest has increased in defining factors that possibly contribute to brain functional plasticity; the results might be useful to assess the relationship between MS lesion burden and clinical events, as well as explaining the well-known phenotypic heterogeneity of the disease. In this study, we explored the effect of the Val66Met brain-derived neurotrophic factor (BDNF) functional polymorphism on cognitive performances and volumetric measurements obtained by magnetic resonance imaging of the brain in a selected population of relapsing-remitting MS (RRMS) patients, with relatively short disease duration and minimal clinical disability, compared to gender, age and educational-level matched healthy subjects. We found that in the RRMS group, the BDNF Met-allele was significantly associated with the lower volume of cerebral grey matter (GM) (P = 0.005). Furthermore, a significant (P = 0.013) interaction effect between 'MS-status' and the BDNF genotype was found for GM volumes, with the result that patients carrying the BDNF Met-allele showed a higher risk of developing global GM atrophy than the homozygous Val/Val. No BDNF-related impact on global neuropsychological functions resulted in either RRMS patients or controls. Our data seem to be consistent with the reported influence of BDNF in neuronal plasticity, thus suggesting that the Met-allele might have a negative prognostic effect on cortical morphometry in RRMS patients.
Collapse
|